- Price
- $16.29
- Day
- +2.84%
- Mkt Cap
- $418.57M
- 52W Range
- $5.37 – $16.31
- Volume
- 2.63M
- Beta
- 1.73
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read full article
On July 31, 2026, NeoGenomics Inc (NEO) shares fell 3.7% to $15.29, reflecting a mixed price performance amid broader market movements. The stock has traded wit
Read full article
NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) reached a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The stock traded as high as $16.10 and last traded at $15.5070, with a volume of 629708 shares changing hands. The stock had previously closed at $13.40. The medical research company reported
Read full article
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2026.
Read full article
American Capital Management Inc. lowered its position in shares of NeoGenomics, Inc. (NASDAQ: NEO) by 3.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,250,878 shares of the medical research company's stock after selling 73,488 shares
Read full article
NeoGenomics NASDAQ: NEO raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing.
Read full article
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
Read full article
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Read full article
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS.
Read full article
CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written feedback from the U.S. Food and Drug Administration (“FDA”) regarding the chemistry, manufacturing and controls (“CMC”) development program for NEO212, the Company's novel temozolomide-perillyl alcohol conjugate.
Read full article